重症患者经验性广谱抗生素相关肾毒性的大规模多中心回顾性研究
该回顾性队列研究利用eICU Research Institute 2010至2015年335家医院的ICU数据,纳入35,654例接受万古霉素联合哌拉西林-他唑巴坦、头孢吡肟或美罗培南的患者,以KDIGO 2或3期急性肾损伤为主要终点,采用倾向评分匹配计算OR。万古霉素联合哌拉西林-他唑巴坦较联合头孢吡肟(AKI OR 1.37,95%CI 1.25-1.49;透析 OR 1.28,95%CI 1.14-1.45)和联合美罗培南(AKI OR 1.27,95%CI 1.06-1.52;透析 OR 1.56,95%CI 1.23-2.00)肾损伤风险更高。作者认为在ICU患者中可考虑万古霉素联合美罗培南或头孢吡肟以降低肾毒性风险。
要点
- 与万古霉素联合头孢吡肟相比,万古霉素联合哌拉西林-他唑巴坦与急性肾损伤风险升高相关(OR 1.37,95%CI 1.25-1.49)及透析启动风险升高相关(OR 1.28,95%CI 1.14-1.45)。
- 与万古霉素联合美罗培南相比,万古霉素联合哌拉西林-他唑巴坦与急性肾损伤风险升高相关(OR 1.27,95%CI 1.06-1.52)及透析启动风险升高相关(OR 1.56,95%CI 1.23-2.00)。
- 在初始肾功能正常且接受较长疗程万古霉素联合哌拉西林-他唑巴坦治疗的患者中,急性肾损伤风险升高尤为明显(与万古霉素联合美罗培南比较)。
- 作者认为,临床医生可考虑对ICU患者选用万古霉素联合美罗培南或万古霉素联合头孢吡肟以降低肾毒性风险。
适用人群与场景
- ICU患者,纳入初始收入急诊科且仅接受万古霉素联合哌拉西林-他唑巴坦、万古霉素联合头孢吡肟或万古霉素联合美罗培南之一者。
- 排除住院时间<1小时、接受透析或数据缺失的患者。
诊断标准与关键阈值
- 急性肾损伤定义为基于血清肌酐成分的KDIGO 2期或3期。
处置流程与药物剂量
- 作者认为,临床医生可考虑对ICU患者选用万古霉素联合美罗培南或万古霉素联合头孢吡肟以降低肾毒性风险。
研究设计与关键结果
- 回顾性队列研究,使用eICU Research Institute 2010至2015年335家医院的ICU记录,共35,654例符合标准:万古霉素联合哌拉西林-他唑巴坦27,459例,万古霉素联合头孢吡肟6,371例,万古霉素联合美罗培南1,824例。
- 采用倾向评分匹配后计算OR;与万古霉素联合头孢吡肟相比,万古霉素联合哌拉西林-他唑巴坦的急性肾损伤OR为1.37(95%CI 1.25-1.49),透析启动OR为1.28(95%CI 1.14-1.45)。
- 与万古霉素联合美罗培南相比,万古霉素联合哌拉西林-他唑巴坦的急性肾损伤OR为1.27(95%CI 1.06-1.52),透析启动OR为1.56(95%CI 1.23-2.00)。
- 敏感性分析显示,在无肾功能不全且接受较长疗程万古霉素联合哌拉西林-他唑巴坦治疗的患者中,急性肾损伤风险升高尤为明显(与万古霉素联合美罗培南比较)。
证据类型、等级与局限
- 证据类型:多中心回顾性队列研究(335家医院)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,临床医生可考虑对ICU患者选用万古霉素联合美罗培南或万古霉素联合头孢吡肟以降低肾毒性风险;尤其对初始肾功能正常且需较长疗程者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Evidence regarding acute kidney injury associated with concomitant administration of vancomycin and piperacillin-tazobactam is conflicting, particularly in patients in the ICU.
RESEARCH QUESTION: Does a difference exist in the association between commonly prescribed empiric antibiotics on ICU admission (vancomycin and piperacillin-tazobactam, vancomycin and cefepime, and vancomycin and meropenem) and acute kidney injury?
STUDY DESIGN AND METHODS: This was a retrospective cohort study using data from the eICU Research Institute, which contains records for ICU stays between 2010 and 2015 across 335 hospitals. Patients were enrolled if they received vancomycin and piperacillin-tazobactam, vancomycin and cefepime, or vancomycin and meropenem exclusively. Patients initially admitted to the ED were included. Patients with hospital stay duration of < 1 h, receiving dialysis, or with missing data were excluded. Acute kidney injury was defined as Kidney Disease: Improving Global Outcomes stage 2 or 3 based on serum creatinine component. Propensity score matching was used to match patients in the control (vancomycin and meropenem or vancomycin and cefepime) and treatment (vancomycin and piperacillin-tazobactam) groups, and ORs were calculated. Sensitivity analyses were performed to study the effect of longer courses of combination therapy and patients with renal insufficiency on admission.
RESULTS: Thirty-five thousand six hundred fifty-four patients met inclusion criteria (vancomycin and piperacillin-tazobactam, n = 27,459; vancomycin and cefepime, n = 6,371; vancomycin and meropenem, n = 1,824). Vancomycin and piperacillin-tazobactam was associated with a higher risk of acute kidney injury and initiation of dialysis when compared with that of both vancomycin and cefepime (Acute kidney injury: OR, 1.37 [95% CI, 1.25-1.49]; dialysis: OR, 1.28 [95% CI, 1.14-1.45]) and vancomycin and meropenem (Acute kidney injury: OR, 1.27 [95%, 1.06-1.52]; dialysis: OR, 1.56 [95% CI, 1.23-2.00]). The odds of acute kidney injury developing was especially pronounced in patients without renal insufficiency receiving a longer duration of vancomycin and piperacillin-tazobactam therapy compared with vancomycin and meropenem therapy.
INTERPRETATION: VPT is associated with a higher risk of acute kidney injury than both vancomycin and cefepime and vancomycin and meropenem in patients in the ICU, especially for patients with normal initial kidney function requiring longer durations of therapy. Clinicians should consider vancomycin and meropenem or vancomycin and cefepime to reduce the risk of nephrotoxicity for patients in the ICU.
参考来源
- Chen AY, Deng CY, Calvachi-Prieto P, et al. A Large-Scale Multicenter Retrospective Study on Nephrotoxicity Associated With Empiric Broad-Spectrum Antibiotics in Critically Ill Patients. Chest. 2023. PMID: 37040818. doi:10.1016/j.chest.2023.03.046
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。